Literature DB >> 16989618

A rapid and sensitive real-time PCR assay for the K65R drug resistance mutation in SIV reverse transcriptase.

Jeffrey A Johnson1, Koen K A Van Rompay, Eric Delwart, Walid Heneine.   

Abstract

Macaques infected with simian immunodeficiency virus (SIV) provide a suitable model for assessing the efficacy of antiretroviral (ARV) drug interventions and drug resistance selection associated with treatment. Resistance to the HIV reverse transcriptase inhibitor tenofovir continues to be examined in different treatment strategies in the macaque model. Evaluations of treatment interventions and drug resistance are hampered by the limited sensitivity of conventional population sequencing and the substantial effort involved in testing various tissue compartments in which viruses may reside. Therefore, a sensitive assay that permits simple and rapid testing for drug-resistant viruses would benefit appraisals of ARV treatments using in vivo models. To have this capability, we developed a real-time PCR-based assay for the detection of the SIV K65R reverse transcriptase mutation, a key marker for reduced susceptibility to tenofovir. Evaluations of SIV sequences yielded an assay detection limit mean of 0.4% mutant virus (range = 0.1-2%) in a wild-type background. In testing longitudinal plasma specimens from four SIV-infected macaques that received an active daily regimen of 30 mg/kg of tenofovir subcutaneously, the assay was able to detect K65R-positive viruses in all animals within 1-7 weeks after treatment began. The emerging mutants were initially present at frequencies estimated between 0.4% and 3%, below the detection capability of population sequencing. We propose the SIV K65R real-time PCR assay provides improved sensitivity and simplicity in studying tenofovir resistance in macaque models.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16989618     DOI: 10.1089/aid.2006.22.912

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  9 in total

1.  Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.

Authors:  Charles Dobard; Sunita Sharma; Amy Martin; Chou-Pong Pau; Angela Holder; Zsuzsanna Kuklenyik; Jonathan Lipscomb; Debra L Hanson; James Smith; Francis J Novembre; J Gerardo García-Lerma; Walid Heneine
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Compared to subcutaneous tenofovir, oral tenofovir disoproxyl fumarate administration preferentially concentrates the drug into gut-associated lymphoid cells in simian immunodeficiency virus-infected macaques.

Authors:  Koen K A Van Rompay; Darius Babusis; Zachary Abbott; Yongzhi Geng; Kartika Jayashankar; Jeffrey A Johnson; Jonathan Lipscomb; Walid Heneine; Kristina Abel; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2012-07-09       Impact factor: 5.191

3.  Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques.

Authors:  Koen K A Van Rompay; Raman P Singh; Walid Heneine; Jeffrey A Johnson; David C Montefiori; Norbert Bischofberger; Marta L Marthas
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  Tenofovir disoproxil fumarate intravaginal ring protects high-dose depot medroxyprogesterone acetate-treated macaques from multiple SHIV exposures.

Authors:  James M Smith; Priya Srinivasan; Ryan S Teller; Yungtai Lo; Chuong T Dinh; Patrick F Kiser; Betsy C Herold
Journal:  J Acquir Immune Defic Syndr       Date:  2015-01-01       Impact factor: 3.731

5.  Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors.

Authors:  J Gerardo García-Lerma; Wutyi Aung; Mian-er Cong; Qi Zheng; Ae S Youngpairoj; James Mitchell; Angela Holder; Amy Martin; Susan Kuklenyik; Wei Luo; Carol Yen-Chin Lin; Debra L Hanson; Ellen Kersh; Chou-Pong Pau; Adrian S Ray; James F Rooney; William A Lee; Walid Heneine
Journal:  J Virol       Date:  2011-04-27       Impact factor: 5.103

6.  Rapid adaptive amplification of preexisting variation in an RNA virus.

Authors:  Ranendra N Dutta; Igor M Rouzine; Sarah D Smith; Claus O Wilke; Isabel S Novella
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

7.  Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal.

Authors:  Koen K A Van Rompay; Kristin A Trott; Kartika Jayashankar; Yongzhi Geng; Celia C LaBranche; Jeffrey A Johnson; Gary Landucci; Jonathan Lipscomb; Ross P Tarara; Don R Canfield; Walid Heneine; Donald N Forthal; David Montefiori; Kristina Abel
Journal:  Retrovirology       Date:  2012-07-17       Impact factor: 4.602

8.  Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.

Authors:  Koen K A Van Rompay; Jeffrey A Johnson; Emily J Blackwood; Raman P Singh; Jonathan Lipscomb; Timothy B Matthews; Marta L Marthas; Niels C Pedersen; Norbert Bischofberger; Walid Heneine; Thomas W North
Journal:  Retrovirology       Date:  2007-04-06       Impact factor: 4.602

9.  Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir.

Authors:  J Gerardo García-Lerma; Ron A Otten; Shoukat H Qari; Eddie Jackson; Mian-Er Cong; Silvina Masciotra; Wei Luo; Caryn Kim; Debra R Adams; Michael Monsour; Jonathan Lipscomb; Jeffrey A Johnson; David Delinsky; Raymond F Schinazi; Robert Janssen; Thomas M Folks; Walid Heneine
Journal:  PLoS Med       Date:  2008-02       Impact factor: 11.069

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.